Long-term follow-up of antibody titers after hepatitis A vaccination

1993 ◽  
Vol 1 (4) ◽  
pp. 194-199 ◽  
Author(s):  
I KURAMOTO ◽  
S FUJIYAMA ◽  
K ODOH ◽  
K MIZUNO ◽  
T SATO
Keyword(s):  
Hepatitis A ◽  
Long Term Follow Up ◽  
Antibody Titers

Chronic Non-A, Non-B Hepatitis: A Long-Term Follow-up Study in 49 Patients

1987 ◽  
Vol 22 (9) ◽  
pp. 1115-1122 ◽  
Author(s):  
R. Wejstål ◽  
J. Lindberg ◽  
P. Lundin ◽  
G. Norkrans
Keyword(s):  
Hepatitis A ◽  
Follow Up Study ◽  
Long Term Follow Up

Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients

2009 ◽  
Vol 50 (2) ◽  
pp. 388-393 ◽  
Author(s):  
Mårten Werner ◽  
Sven Almer ◽  
Hanne Prytz ◽  
Stefan Lindgren ◽  
Sven Wallerstedt ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Long Term Follow Up

Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis – a long-term follow-up study in 634 Swedish patients

2014 ◽  
Vol 50 (2) ◽  
pp. 217-223 ◽  
Author(s):  
Åsa Danielsson Borssén ◽  
Sven Almer ◽  
Hanne Prytz ◽  
Sven Wallerstedt ◽  
Inga-Lill Friis-Liby ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Hepatitis A ◽  
Follow Up Study ◽  
Long Term Follow Up

An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 1008-1008 ◽  
Author(s):  
T. F. Schwarz
Keyword(s):  
Sexual Debut ◽  
Geometric Mean ◽  
Phase Iii ◽  
Cervical Lesions ◽  
Hpv 16 ◽  
Long Term Follow Up ◽  
Antibody Titers ◽  
Antibody Levels

1008 Background: Genital HPV infections can be acquired shortly after sexual debut, and the risk remains throughout a sexually active woman’s lifetime. In women 15–25 years of age, the AS04-containing HPV vaccine was highly immunogenic and conferred 100% protection against HPV-16/18 persistent infection and associated cervical lesions up to 27 months. In the long-term follow-up of this study, sustained vaccine efficacy has been observed up to 48 months. The present phase III study (580299/014) assessed immune responses to the AS04-containing HPV-16/18 vaccine in women 26–55 years old compared with women 15–25 years old. Methods: Healthy women in Germany and Poland between 15 and 55 years of age received 3 doses of HPV-16/18 AS04-containing vaccine at months 0, 1, and 6. The groups were age stratified: 15–25 (n=229), 26–45 (n=226), and 46–55 (n=211). Anti-HPV-16/18 antibody titers were assessed at months 0, 2, 7, and 12 by ELISA (EU/mL). Seropositivity rates and geometric mean antibody titers (GMTs) were calculated for all groups. Safety was assessed after each dose in all participants. Results: All initially seronegative women became seropositive for both HPV 16 and 18 at Month 2. At Month 7, HPV-16 GMTs (95% CI) were 7908.4 (6874.0–9098.5) in 15–25 year olds, 4029.2 (3402.7–4771.0) in 26–45 year olds, and 2566.8 (2181.2–3020.6) in 46–55 year olds. For HPV-18, GMTs were 3499.3 (3098.7–3951.6) in 15–25 year olds, 1837.3 (1602.1–2107.0) in 26–45 year olds, and 1313.0 (1145.6–1504.9) in 46–55 year olds. Overall the vaccine was well-tolerated, and the incidence of local symptoms (within 30 days) tended to be lower in the 46–55 year-old group (69.2% versus 81.6% [26–45] and 85.7% [15–25]). Conclusions: An AS04-containing HPV-16/18 vaccine was immunogenic and generally safe in 15–55 year-old females. As observed with other vaccines, GMTs decreased with age, however, the Month 7 postvaccination antibody levels in the oldest age group (46–55) were still 3–4 times higher than those observed during a separate long-term follow-up study where sustained efficacy has been observed up to 48 months. [Table: see text]

Long-term follow-up of hepatitis A vaccination in children

Vaccine ◽  
1999 ◽  
Vol 17 (4) ◽  
pp. 369-372 ◽  
Author(s):  
Cho-Yu Chan ◽  
Shou-Dong Lee ◽  
May-Ing Yu ◽  
Yuan-Jen Wang ◽  
Full-Young Chang ◽  
...  
Keyword(s):  
Hepatitis A ◽  
Long Term Follow Up

Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A long-term follow-up study

2008 ◽  
Vol 7 (2) ◽  
pp. 96-105 ◽  
Author(s):  
Kirsten D. Bentsen ◽  
KIM Hørslev-Petersen ◽  
Peter Junker ◽  
Erik Juhl ◽  
Ib Lorenzen ◽  
...  
Keyword(s):  
Viral Hepatitis ◽  
Hepatitis A ◽  
Acute Viral Hepatitis ◽  
Procollagen Type ◽  
Follow Up Study ◽  
Long Term Follow Up ◽  
Viral Hepatitis A ◽  
Acute Viral Hepatitis A

scholarly journals Long COVID in a prospective cohort of home-isolated patients

2021 ◽  
Author(s):  
Bjørn Blomberg ◽  
Kristin Greve-Isdahl Mohn ◽  
Karl Albert Brokstad ◽  
Fan Zhou ◽  
Dagrun Waag Linchausen ◽  
...  
Keyword(s):  
Prospective Cohort ◽  
Control Measures ◽  
Persistent Symptoms ◽  
Infection Control Measures ◽  
Memory Problems ◽  
Long Term Follow Up ◽  
Antibody Titers ◽  
Pandemic Wave

AbstractLong-term complications after coronavirus disease 2019 (COVID-19) are common in hospitalized patients, but the spectrum of symptoms in milder cases needs further investigation. We conducted a long-term follow-up in a prospective cohort study of 312 patients—247 home-isolated and 65 hospitalized—comprising 82% of total cases in Bergen during the first pandemic wave in Norway. At 6 months, 61% (189/312) of all patients had persistent symptoms, which were independently associated with severity of initial illness, increased convalescent antibody titers and pre-existing chronic lung disease. We found that 52% (32/61) of home-isolated young adults, aged 16–30 years, had symptoms at 6 months, including loss of taste and/or smell (28%, 17/61), fatigue (21%, 13/61), dyspnea (13%, 8/61), impaired concentration (13%, 8/61) and memory problems (11%, 7/61). Our findings that young, home-isolated adults with mild COVID-19 are at risk of long-lasting dyspnea and cognitive symptoms highlight the importance of infection control measures, such as vaccination.

Long-term follow-up of hepatitis A vaccination in patients with chronic liver disease

2000 ◽  
Vol 118 (4) ◽  
pp. A1462
Author(s):  
Shou-Dong Lee ◽  
May-Ing Yu ◽  
Cho-Yu Chan ◽  
Yuan-Jen Wang ◽  
Full-Young Chang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Hepatitis A ◽  
Chronic Liver ◽  
Long Term Follow Up

scholarly journals Long-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome

2019 ◽  
Vol 10 (3) ◽  
pp. e0020
Author(s):  
Halim Awadie ◽  
Johad Khoury ◽  
Yaniv Zohar ◽  
Afif Yaccob ◽  
Ella Veitsman ◽  
...  
Keyword(s):  
Hepatitis A ◽  
Hypereosinophilic Syndrome ◽  
Rare Presentation ◽  
Long Term Follow Up

scholarly journals Comparative quantitative analysis of SARS-CoV-2 Spike neutralizing antibody titers following two anti COVID-19 vaccines in India

2021 ◽  
Author(s):  
Chanukya GV ◽  
Aparna Srikantam
Keyword(s):  
Quantitative Analysis ◽  
Neutralizing Antibodies ◽  
Large Scale ◽  
Neutralizing Antibody ◽  
Long Term Follow Up ◽  
Antibody Titers ◽  
Age Studies ◽  
Immunogenic Response

In COVID 19 pandemic, first line of defense is effective vaccination program. Because of multiple platforms available for vaccine production we tested relative immunogenicity of two vaccines available in India, Covaxin and Covishield We performed quantitative analysis of neutralizing antibodies to SARS Cov2 spike (receptor binding domain ) protein, from sera of 53 subjects who completed vaccines schedules. There was significantly higher immunogenic response with Covishield as compared to Covaxin and are independent of age. Studies on a large scale with long term follow up are needed to further advance the knowledge in this domain.

Sign in / Sign up

Export Citation Format

Share Document